3wl9 Citations

Switching and emergence of CTL epitopes in HIV-1 infection.

Abstract

Background
Results

Two overlapping epitopes in HIV-1 nef, Nef126-10 and Nef134-10, elicit the most frequent CTL responses restricted by HLA-A*24:02. Thirty-five of 46 (76%) HLA-A*24:02-positive patients harbored the Y135F mutation in their plasma HIV-1 RNA. Nef codon 135 plays a crucial role in both epitopes, as it represents the C-terminal anchor for Nef126-10 and the N-terminal anchor for Nef134-10. While the majority of patients with 135F exhibited CTL responses to Nef126-10, none harboring the "wild-type" (global HIV-1 subtype B consensus) Y135 did so, suggesting that Nef126-10 is not efficiently presented in persons harboring Y135. Consistent with this, peptide binding and limiting dilution experiments confirmed F, but not Y, as a suitable C-terminal anchor for HLA-A*24:02. Moreover, experiments utilizing antigen specific CTL clones to recognize endogenously-expressed peptides with or without Y135F indicated that this mutation disrupted the antigen expression of Nef134-10. Critically, the selection of Y135F also launched the expression of Nef126-10, indicating that the latter epitope is created as a result of escape within the former.

Conclusion

Our data represent the first example of the de novo creation of a novel overlapping CTL epitope as a direct result of HLA-driven immune escape in a neighboring epitope. The robust targeting of Nef126-10 following transmission (or in vivo selection) of HIV-1 containing Y135F may explain in part the previously reported stable plasma viral loads over time in the Japanese population, despite the high prevalence of both HLA-A*24:02 and Nef-Y135F in circulating HIV-1 sequences.

Articles - 3wl9 mentioned but not cited (9)

  1. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research. Chen Z, Ruan P, Wang L, Nie X, Ma X, Tan Y. J Cell Mol Med 25 1274-1289 (2021)
  2. Identification of a tumor-specific allo-HLA-restricted γδTCR. Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, Falkenburg JH, Bongiovanni L, de Bruin A, Vargas-Diaz D, Altelaar M, Heck AJR, Shultz LD, Ishikawa F, Nishimura MI, Sebestyén Z, Kuball J. Blood Adv 3 2870-2882 (2019)
  3. PANDORA: A Fast, Anchor-Restrained Modelling Protocol for Peptide: MHC Complexes. Marzella DF, Parizi FM, van Tilborg D, Renaud N, Sybrandi D, Buzatu R, Rademaker DT, 't Hoen PAC, Xue LC. Front Immunol 13 878762 (2022)
  4. Identification of Conserved Peptides Comprising Multiple T Cell Epitopes of Matrix 1 Protein in H1N1 Influenza Virus. Lohia N, Baranwal M. Viral Immunol 28 570-579 (2015)
  5. A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry. Bezstarosti S, Bakker KH, Kramer CSM, de Fijter JW, Reinders MEJ, Mulder A, Claas FHJ, Heidt S. Front Immunol 12 800946 (2021)
  6. Immunogenicity and antigenicity based T-cell and B-cell epitopes identification from conserved regions of 10664 SARS-CoV-2 genomes. Ghosh N, Sharma N, Saha I. Infect Genet Evol 92 104823 (2021)
  7. Highly conserved hemagglutinin peptides of H1N1 influenza virus elicit immune response. Lohia N, Baranwal M. 3 Biotech 8 492 (2018)
  8. Releasing the concept of HLA-allele specific peptide anchors in viral infections: A non-canonical naturally presented human cytomegalovirus-derived HLA-A*24:02 restricted peptide drives exquisite immunogenicity. Pump WC, Schulz R, Huyton T, Kunze-Schumacher H, Martens J, Hò GT, Blasczyk R, Bade-Doeding C. HLA 94 25-38 (2019)
  9. HLAs associated with perampanel-induced psychiatric adverse effects in a Korean population. Jang Y, Kim TJ, Moon J, Yang TW, Kim KT, Park BS, Lim JA, Jun JS, Lee ST, Jung KH, Park KI, Jung KY, Chu K, Lee SK. Sci Rep 10 13667 (2020)


Reviews citing this publication (1)

  1. Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure. Avila-Rios S, Carlson JM, John M, Mallal S, Brumme ZL. Curr Opin HIV AIDS 14 194-204 (2019)

Articles citing this publication (9)